KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

Despite curative-intent treatment, most patients with locally advanced esophageal cancer will experience disease recurrence or locoregional progression, highlighting the need for new therapies. Current guidelines recommend definitive chemoradiotherapy in patients ineligible for surgical resection, b...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Future Oncol
Auteurs principaux: Shah, Manish A, Bennouna, Jaafar, Doi, Toshihiko, Shen, Lin, Kato, Ken, Adenis, Antoine, Mamon, Harvey J, Moehler, Markus, Fu, Xiaolong, Cho, Byoung Chul, Bordia, Sonal, Bhagia, Pooja, Shih, Chie-Schin, Desai, Anjali, Enzinger, Peter
Format: Artigo
Langue:Inglês
Publié: Future Medicine Ltd 2021
Sujets:
Clinical Trial Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7927908/
https://ncbi.nlm.nih.gov/pubmed/33533655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0969
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires